Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients

British Journal of Haematology

Volumn 129, Issue 6, 2005, Pages 771-775

  Cervantes, Francisco ^a,b   Alvarez Larrán, Alberto ^a   Domingo, Abel ^a   Arellano Rodrigo, Eduardo ^a   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Androgens; Danazol; Myelofibrosis with myeloid metaplasia; Therapy

Indexed keywords

ALPHA INTERFERON; ANAGRELIDE; ANDROGEN; CYCLOSPORIN A; DANAZOL; HYDROXYUREA; PREDNISONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ANEMIA OF MYELOFIBROSIS WITH MYELOID METAPLASIA; ARTICLE; CHOLESTATIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; LIVER ADENOMA; LIVER FUNCTION TEST; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; MYELOFIBROSIS; MYELOID METAPLASIA; PELIOSIS HEPATIS; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; SPLENECTOMY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DANAZOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 21344468831     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05524.x     Document Type: Article

References (21)

1. Ahn, Y.S., Harrington, W.J., Simon, S.R., Mylvaganam, R., Pall, L.M. & So, A.G. (1983) Danazol for the treatment of idiopathic thrombocytopenic purpura. New England Journal of Medicine, 308, 1396-1399.
2. Ahn, Y.S., Harrington, W.J., Mylvaganam, M., Ayub, J. & Pall, L.M. (1985) Danazol therapy for autoimmune haemolytic anemia. Annals of Internal Medicine, 102, 298-301.
3. Barosi, G., Ambrosetti, A., Finelli, G., Grossi, A., Leoni, P., Liberato, N.L., Petti, M.C., Pogliani, E., Ricetti, M., Rupoli, S., Visani, G. & Tura, S. (1999) The Italian consensus conference on diagnostic criteria for myelofibrosis with myeloid metaplasia. British Journal of Haematology, 104, 730-737.
4. Barosi, G., Grossi, A., Comotti, B., Musto, P., Gamba, G. & Marchetti, M. (2001) Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 114, 78-83.
5. Besa, E.C., Nowell, P.C., Geller, N.L. & Gardner, F.H. (1982) Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer, 49, 308-313.
6. Brubaker, L.H., Briere, J., Laszlo, J., Kraut, E., Landaw, S.A., Peterson, P., Goldberg, J. & Donovan, P. (1982) Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only. Archives of Internal Medicine, 142, 1533-1537.
7. Cervantes, F., Hernández-Boluda, J.C., Alvarez, A., Nadal, E. & Montserrat, E. (2000) Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica, 85, 595-599.
8. Cervantes, F., Alvarez-Larrán, A., Hernández-Boluda, J.C., Sureda, A., Torrebadell, M. & Montserrat, E. (2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology, 127, 399-403.
9. Chabannon, C., Pegourie, B., Sotto, J.J. & Hollard, D. (1990) Clinical and haematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouvelle Revue Française d'Hematologie, 32, 165-166.
10. Cortes, J., Albitar, M., Thomas, D., Giles, F., Kurzrock, R., Thibault, A., Rackoff, W., Koller, C., O'Brien, S., Garcia-Manero, G., Talpaz, M. & Kantarjian, H. (2003) Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood, 101, 1692-1697.
11. Giles, F.J., Cooper, M.A., Silverman, L., Karp, J.E., Lancet, J.E., Zangari, M., Shami, P.J., Khan, K.D., Hannah, A.L., Cherrington, J.M., Thomas, D.A., Garcia-Manero, G., Albitar, M., Kantarjian, H.M. & Stopeck, A.T. (2003) Phase II study of SU5416 - a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor - in patients with refractory myeloproliferative diseases. Cancer, 97, 1920-1928.
12. Hasselbalch, H.C., Clausen, N.T. & Jensen, B.A. (2002) Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin. American Journal of Hematology, 70, 92-99.
13. Hast, R., Engstedt, L., Jameson, S., Killander, A., Lundh, B., Reizenstein, P., Skarberg, K.O., Uden, A.M. & Wadman, B. (1978) Oxymetholone treatment in myelofibrosis. Blut, 37, 19-26.
14. Jacobson, R.J., Salo, A. & Fialkow, P.J. (1978) Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood, 51, 189-194.
15. Kennedy, B.J. (1962) Effect of androgenic hormone in myelofibrosis. JAMA, 182, 114-119.
16. Lennert, K., Naghai, K. & Schwarze, E.W. (1975) Patho-anatomical features of the bone marrow. Clinics in Haematology, 43, 331-351.
17. Levy, V., Bourgarit, A., Delmer, A., Legrand, O., Baudard, M., Rio, B. & Zittoun, R. (1996) Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. American Journal of Hematology, 53, 239-241.
18. Mesa, R.A., Steensma, D.P., Pardanani, A., Li, C.Y., Elliott, M., Kaufmann, S.H., Wiseman, G., Gray, L.A., Schoeder, G., Reeder, T., Zeldis, J.B. & Tefferi, A. (2003) A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood, 101, 2534-2541.
19. Reilly, J.T. (1998) Pathogenesis and management of idiopathic myelofibrosis. Baillière's Clinical Hematology, 11, 751-767.
20. Silver, R.T., Jenkins, Jr, D.E. & Engle, R.L. (1964) Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood, 23, 341-353.
21. Stadtmauer, E.A., Cassileth, P.A., Edelstein, M., Abrahm, J., Schreiber, A.D., Nowell, P.C. & Cines, D.B. (1991) Danazol treatment of myelodysplastic syndromes. British Journal of Haematology, 77, 502-508.